Related Experiment Video
Updated: May 30, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks
Juan-Jie Bo1, Chao Zhang, Lian-Hua Zhang
1Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China.
Asian Journal of Andrology
|July 26, 2011
Summary
Androgen deprivation therapy (ADT) for prostate cancer patients may lead to unfavorable metabolic changes, including increased insulin, LDL, and waist circumference. The study highlights the need to balance ADT benefits against these metabolic risks.
Area of Science:
- Oncology
- Endocrinology
- Metabolic Health
Background:
- Prostate cancer is a common male malignancy.
- Androgen deprivation therapy (ADT) is a standard treatment for prostate cancer.
- Previous studies suggest ADT may negatively impact metabolic health.
Purpose of the Study:
- To prospectively investigate the metabolic effects of ADT in prostate cancer patients.
- To compare metabolic profiles between ADT-treated patients, non-ADT prostate cancer patients, and healthy controls.
Main Methods:
- Prospective study with 133 male participants.
- Three groups: ADT (orchiectomy + flutamide), non-ADT (radical prostatectomy), and healthy controls.
- Follow-up for at least 12 months with metabolic parameter measurements.
Main Results:
- ADT group showed increased fasting serum insulin and LDL at 3 months.
- After 12 months, ADT group had increased waist circumference, insulin, glucose, total cholesterol, HDL, and LDL.
- Metabolic syndrome morbidity was significantly higher in the ADT group.
Conclusions:
- ADT, particularly surgical castration, is associated with adverse metabolic alterations in prostate cancer patients.
- These metabolic changes include increased adiposity, dyslipidemia, and hyperglycemia.
- Clinical decisions regarding ADT should carefully weigh therapeutic benefits against metabolic risks.
